Stockreport

Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed [Yahoo! Finance]

Tenaya Therapeutics, Inc.  (TNYA) 
PDF that the FDA has lifted the clinical hold on its MyPEAK-1 trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, while also completing a US$60,000,000 units [Read more]